The Motley Fool Podcasts Industry Focus Healthcare: Is Amarin's Fish Oil Pill On Track To Become a Blockbuster? Plus, How Gene Editing Company CRISPR Therapeutics Just Took A Big Step Forward

Healthcare: Is Amarin's Fish Oil Pill On Track To Become a Blockbuster? Plus, How Gene Editing Company CRISPR Therapeutics Just Took A Big Step Forward Logo

Healthcare: Is Amarin's Fish Oil Pill On Track To Become a Blockbuster? Plus, How Gene Editing Company CRISPR Therapeutics Just Took A Big Step Forward

Amarin's shares rocketed higher after a key FDA committee recommended expanding the label of its triglycerides lowering drug, Vascepa, to include data showing it can reduce the risk of heart attack and stroke. Meanwhile, shares in CRISPR Therapeutics and partner Vertex Pharmaceuticals are also soaring following the release of interim, early-stage results for its gene-editing therapy for beta thalassemia and sickle cell disease therapy. Stocks: AMRN, CRSP, VRTX

Check out more of our content here:

Nov 20,2019  •   24:24
Listen to Healthcare: Is Amarin's Fish Oil Pill On Track To Become a Blockbuster? Plus, How Gene Editing Company CRISPR Therapeutics Just Took A Big Step Forward

Recent Episodes

Healthcare: How To Profit From The Massive Aging-In-Place Trend

The number of Americans over age 65 and age 85 will double and triple, by 2050, respectively; and many of these seniors will want to stay in their homes as long as possible.  In today's show, Shannon Jones interviews Mark Switaj, CEO of Roundtrip, a  privately held investment with our sister company, Motley Fool Ventures, to discuss aging in place and why investors ought to be paying attention. Also, healthcare investor Todd Campbell joins Jones to highlight a handful of companies that could benefit big from this emerging trend, including LHC Group, Teladoc, and Livongo Health. Stocks: LHCG, TDOC, LVGO, ADT, AMZN, CVS

Dec 11, 2019  •   40:44  •   Industry Focus
Listen

CG: An Interview With Brightline's Sophia Moshasha, Co-Host of the "Everything VR & AR" Podcast

On this week’s episode of Industry Focus: Consumer Goods host Jason Moser sits down with Brightline Interactive's Sophia Moshasha, co-host of the Everything VR & AR podcast to talk more about the future of AR, VR, and MR, as well as the state of women in tech and much more!

Get the first $50 off at LinkedIn.com/fool

 

Dec 10, 2019  •   29:19  •   Industry Focus
Listen

Financials: The Evolving Role of Women in Finance and 5 Bold Predictions for 2020

In this week’s installment of Industry Focus: Financials, host Jason Moser sits down for an interview with Caroline Feeney, CEO of Individual Solutions for Prudential Financial to discuss the evolving role of women in the financial industry. Plus, Moser and Fool.com contributor Matt Frankel, CFP take a closer look at five bold stock market predictions for 2020. Spoiler alert: They’re a bit more negative than last year’s.

Check out more of our content here:

Dec 09, 2019  •   38:14  •   Industry Focus
Listen

Energy: How to Invest in LNG

Global trends toward reducing pollution have natural gas demand poised to spike in the coming years. At the same time, fracking has opened up massive surpluses of natural gas in the United States, pushing domestic natural gas prices well below those around the globe. Together, these developments create a massive opportunity to export natural gas from the U.S. to the rest of the world. To do that, requires turning natural gas into a liquid, also known as liquefied natural gas (LNG).

Motley Fool contributor Jason Hall joins the show to break down the opportunity and discuss ways to invest in LNG, from pure-plays, to picks and shovels, to lower risk integrated producers, midstream players, and utilities. 

Stocks Mentioned: LNG, TELL, NEXT, GTLS, RDS-A, RDS-B, CVX, KMI, D

Check out more of our content here:



Dec 05, 2019  •   37:39  •   Industry Focus
Listen

Healthcare: Can Cannabis 2.0 Kickstart Marijuana Stocks? Plus, Why Novartis' Is Making A $10 Billion Bet

Second generation marijuana products including edibles and beverages launch in Canada's marijuana market this month, but there's still a lot of headwinds facing marijuana stocks. Is it safe to buy? Also, the potential to reshape how doctors treat patients at risk of cardiovascular disease has led to Novartis acquiring The Medicines Company for $9.7 billion. Will this be money well spent?

Check out more of our content here:

Dec 04, 2019  •   30:35  •   Industry Focus
Listen